# ILC CDL Ratification Window 270-279 Handoff v0.1

Status: Phase-279 handoff artifact
Date: 2026-02-24
Window closed: 270-279

## 1. Window summary (270-279 completion state)

Window 270-279 completed the following:
- locked the sequence and sensitivity map for phases 270-279,
- completed issuance evidence closure packages B and C,
- ratified `CDL-029` in Phase 272,
- ratified `CDL-026` in Phase 273,
- ratified `CDL-028` in Phase 274,
- ratified `CDL-027` in Phase 276,
- ratified `CDL-030` in Phase 277,
- published integration coherence report and context capsule v0.6 in Phase 278,
- composed and executed closure verification gate in Phase 279.

## 2. Verified ratification state

Verified ratified CDLs in this window:
- `CDL-029` ratified in Phase 272 (`ratified_phase: 272`, `ratified_date: 2026-02-23`) with evidence:
  - `docs/specs/ilc_cdl_029_allocation_split_ratification_evidence_272_v0.1.md`
- `CDL-026` ratified in Phase 273 (`ratified_phase: 273`, `ratified_date: 2026-02-23`) with evidence:
  - `docs/specs/ilc_cdl_026_cmax_lock_ratification_evidence_273_v0.1.md`
- `CDL-028` ratified in Phase 274 (`ratified_phase: 274`, `ratified_date: 2026-02-23`) with evidence:
  - `docs/specs/ilc_cdl_028_fee_burn_split_ratification_evidence_274_v0.1.md`
- `CDL-027` ratified in Phase 276 (`ratified_phase: 276`, `ratified_date: 2026-02-23`) with evidence:
  - `docs/specs/ilc_cdl_027_decay_formulation_ratification_evidence_276_v0.1.md`
- `CDL-030` ratified in Phase 277 (`ratified_phase: 277`, `ratified_date: 2026-02-23`) with evidence:
  - `docs/specs/ilc_cdl_030_ecu_price_clamp_ratification_evidence_277_v0.1.md`

Decision-log anchor:
- `docs/specs/ilc_constitutional_decision_log_v0.1.md`

## 3. Hard prerequisites for Phase 280+ sequence

Before opening the next issuance-ratification sequence:
1. preserve mutation-scope guardrail continuity from Phase 261 (`status`, `ratified_phase`, `ratified_date`, `evidence_document` only),
2. keep phase-scoped non-target assertion convention (`ratified_phase != "{N}"`), never `status == "open"` as a non-target invariant,
3. include expanded cross-phase regression carry-forward:
   - `tests/test_cdl_032_ratification_253.py`
   - `tests/test_security_cdl_ratification_251.py`
   - `tests/test_cdl_025_ratification_267.py`
   - `tests/test_cdl_019_ratification_268.py`
   - `tests/test_cdl_029_ratification_272.py`
   - `tests/test_cdl_026_ratification_273.py`
   - `tests/test_cdl_028_ratification_274.py`
   - `tests/test_cdl_027_ratification_276.py`
   - `tests/test_cdl_030_ratification_277.py`.

## 4. Remaining issuance queue state and deferrals

Remaining issuance queue state after window closure:
- `CDL-031`: open.

Deferral state:
- `CDL-031` is not ratified in the 270-279 window and is explicitly deferred to Phase 280+.

## 5. CDL-031 status note

`CDL-031` has been unblocked since Phase 268 (dependency closure of `CDL-019`), but remains open and unratified in phases 270-279.

No `CDL-031` decision-log mutation was executed in this window.
`CDL-031` is the primary carry-forward item for Phase 280+.

## 6. Non-goals and boundary statement

This window closure does not:
- ratify `CDL-031`,
- mutate any decision-log row in Phase 279,
- modify runtime behavior in `ilc_core/` as part of Phase 279,
- introduce new issuance-policy parameter values in this handoff artifact.

Phase 279 does not mutate any decision-log row and does not modify runtime behavior in `ilc_core/`.

## 7. Canonical anchors and next-sequence pointer

Canonical anchors:
- `docs/specs/ilc_phase_270_279_sequence_lock_v0.1.md`
- `docs/specs/ilc_constitutional_decision_log_v0.1.md`
- `docs/specs/ilc_cdl_029_allocation_split_ratification_evidence_272_v0.1.md`
- `docs/specs/ilc_cdl_026_cmax_lock_ratification_evidence_273_v0.1.md`
- `docs/specs/ilc_cdl_028_fee_burn_split_ratification_evidence_274_v0.1.md`
- `docs/specs/ilc_cdl_027_decay_formulation_ratification_evidence_276_v0.1.md`
- `docs/specs/ilc_cdl_030_ecu_price_clamp_ratification_evidence_277_v0.1.md`
- `docs/specs/ilc_integration_coherence_report_278_v0.1.md`

Next-sequence pointer:
- open Phase 280+ sequence with `CDL-031` as the first ratification candidate, followed by `CDL-033` and ADM-003 lanes.
